IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of IBI112 in
the treatment of participants with moderate to severe psoriasis